| Previous close | 1.1000 |
| Open | 0.6200 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 50.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.6000 - 0.6500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.36k |
GlobeNewswireFulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ― ― Fulcrum will receive an upfront payment of $80.0 million, and is eligible to receive $975.0 million in potential milestones, plus royalties on ex-U.S. product sales; parties will share future global development costs 50:50 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today to discuss the collaboration and other recent corporate d
- GuruFocus.com
Novavax Inc (NVAX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Partnerships and ...
Discover how Novavax Inc (NVAX) is reshaping its future with significant Sanofi collaboration and revised financial projections in Q1 2024.
GlobeNewswireDupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell Current treatment options for adolescents with CRSwNP leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps TARRYTOWN, N.Y. and PARIS, May 13, 2024 (GLOBE NEWSWIRE) -
